A preclinical RAF inhibitor and sister compound to vemurafenib, PLX4720, successfully inhibits MEK and ERK phosphorylation, as well as downstream AKT phosphorylation, in BRAF V600E-mutated astrocytoma cell lines but not in wild-type tumor cell lines [53]. Here, BRAF is linked to neoplasm.